stockportfolio.pro
Stocks / PFE vs VRTX
PFE vs VRTX
Pfizer Inc. and Vertex Pharmaceuticals Incorporated side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
PFE is the larger company ($147.7B vs $116.5B). On the fundamentals, VRTX grows revenue faster (14.1% vs 8.5%); VRTX earns a higher net margin (32.9% vs 12.4%); VRTX has the stronger return on equity (21.2% vs 9.0%). Full numbers below — the stronger figure on each row is in green.
| Pfizer Inc. (PFE) | Vertex Pharmaceuticals Incorporated (VRTX) | |
|---|---|---|
| Market cap | $147.7B | $116.5B |
| Revenue (latest FY) | $62.58B | $12.00B |
| Net income (latest FY) | $7.77B | $3.95B |
| Revenue growth (5y CAGR) | 8.5% | 14.1% |
| Net margin | 12.4% | 32.9% |
| Return on equity | 9.0% | 21.2% |
| P/E ratio | 19.8 | 27.2 |
| Dividend yield | 6.6% | — |
| Profitable years (of last 10) | 10 | 8 |
| Positive free cash flow | Yes | Yes |
Compare with another company:
See the full PFE vs VRTX breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open PFE's full financials → Open VRTX's full financials →More comparisons
Frequently asked questions
Which is bigger, PFE or VRTX?
Pfizer Inc. is larger by market capitalization — $147.7B versus $116.5B.
Which grows faster, PFE or VRTX?
Over the last five fiscal years, Vertex Pharmaceuticals Incorporated grew revenue faster — 14.1%/yr versus 8.5%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.